IL17A and Parkinson disease: Since an increasing number of pharmacological agents are being developed targeting IL-17 and Th17 function, we felt mandatory to establish the role—if any—of Th17 cells and IL-17 in neuroinflammation and neurodegeneration occurring in PD, as this would also pave the way for repositioning Th17/IL-17 targeting drugs in PD.